Small-Cap REIT ETF ...
Health Care: Drugs
PDL BioPharma Inc. (PDLI: NASDAQ)
$8.21 -0.01 | -0.12%
05/20/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 211.67M | 199.39M | 91.87M | 189.66M |
| Operating Gains/Losses | -257.00K | 766.00K | 17.65M | -1.52M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -2.65M | -131.00K | 581.00K | 12.45M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | -4.90M |
| (Decrease) Increase In Payables | 546.00K | -2.01M | 2.17M | -1.35M |
| (Decrease) Increase In Other Current Liabilities | -27.44M | -37.26M | 38.77M | -16.39M |
| (Increase) Decrease In Other Working Capital | -2.70M | -33.58M | 27.68M | 10.24M |
| Other Non-Cash Items | 910.00K | 267.00K | 556.00K | -5.65M |
| Net Cash From Continuing Operations | 210.22M | 169.78M | 184.30M | 186.95M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 210.22M | 169.78M | 184.30M | 186.95M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -51.00K | 0.00 | 0.00 | -39.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -90.30M | 0.00 | 0.00 | 3.47M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -69.42M | -24.05M | -36.90M | 18.43M |
| Issuance of Debt | 0.00 | 149.71M | 82.04M | 285.75M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | -9.90M | 0.00 | 1.40M |
| Repayment of Long-Term Debt | -93.37M | -244.75M | 0.00 | -69.95M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | -83.94M | -83.83M | -130.04M | -319.02M |
| Other Financing Charges, Net | -818.00K | 0.00 | -191.05M | 70.61M |
| Net Cash From Financing Activities | -178.13M | -188.76M | -239.06M | -31.22M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -37.33M | -43.03M | -91.65M | 174.17M |
Portfolios with PDLI
- Portfolio NameUser Type
- ProHighbridge Capital Management
- ContributorEarnings Short Squeeze Play...
- UserSm. Magic July 5 13
- UserMy Stuff
- Userdgr008 Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- UserDividend
- Contributor18 Fundamentally Strong Sto...
- UserGK13
- UserMy current
Latest PDLI Headlines from TheStreet
- 'Mad Money' Lightning Round: Ford Is a Buy 05.16.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Google vs. Apple 05.15.13 | 07:05 pm
- 4 Buy-Rated Dividend Stocks: COP, ETE, PDLI, TEG 05.10.13 | 11:05 am
- 3 Buy-Rated Dividend Stocks 04.26.13 | 11:04 am
- PDL BioPharma (PDLI) Shares Cross Below 200 DMA 04.17.13 | 12:04 pm
- 5 Buy-Rated Dividend Stocks 04.16.13 | 11:04 am
- 3 Buy-Rated Dividend Stocks 04.04.13 | 11:04 am
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- 'Mad Money' Lightning Round: Stay Away From Intel 11.06.12 | 06:11 am
- Cramer's 'Mad Money' Recap: Politics Is Overrated 11.05.12 | 08:11 pm
Press Releases for PDLI
- PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire 03.12.13 | 04:03 pm
- PDL BioPharma To Hold Annual Meeting Of Stockholders On May 21, 2013 - PR Newswire 03.06.13 | 04:03 pm
- PDL BioPharma Announces Conversion Rate Adjustments For Convertible Notes - PR Newswire 03.04.13 | 07:03 am
- PDL BioPharma To Announce Fourth Quarter And Full Year 2012 Financial Results On March 1, 2013 - PR Newswire 02.25.13 | 04:02 pm
- PDL BioPharma To Present At Two Upcoming Investor Conferences - PR Newswire 02.20.13 | 07:02 am
- PDL BioPharma Announces 2013 Regular Quarterly Dividends - PR Newswire 01.30.13 | 07:01 am
- PDL BioPharma Announces Departure Of Finance VP - PR Newswire 01.30.13 | 06:01 am
- PDL BioPharma To Present At The 31st Annual JP Morgan Healthcare Conference - PR Newswire 01.03.13 | 07:01 am
- PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire 12.17.12 | 07:12 am
- PDL BioPharma Announces Conversion Rate Adjustments For Convertible Notes - PR Newswire 12.05.12 | 04:12 pm
Partner Headlines for PDLI
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- After-Hours Earnings Report for March 1, 2013 : VNR, PDLI - NASDAQ 03.01.13 | 07:03 pm
- PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 01, 2013 - NASDAQ 02.27.13 | 02:02 pm
- 8 High-Yielding Dividend Stocks With Very Low PEG Ratios - Seeking Alpha 12.30.12 | 09:12 am
- PDL BioPharma, AxoGen Benefit From 'Royal' Agreement - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions - Benzinga 11.13.12 | 01:11 pm
- These 2 Cramer High-Yield Picks Are Worth Buying In The Market Pullback - Seeking Alpha 11.08.12 | 09:11 am
- Cramer's Lightning Round - Heckmann Is Still A Good Spec (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- PDL BioPharma Beats Zacks Estimates - Analyst Blog - Zacks 08.06.12 | 09:08 am
